Evidence map›Paper›PMID 35497630›Full record

ArticleRSC advances2020

Carbamoyl-

Marina A Alves, Aline C de Queiroz, Anderson Brandão Leite, Felipe T Martins, Antonio C Doriguetto, Eliezer J Barreiro, Magna S Alexandre-Moreira, Lídia M Lima

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marina A AlvesInstituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio, ®), Universidade Federal do Rio de Janeiro (UFRJ), CCS PO Box 68023, Cidade Universitária 21941-902 Rio de Janeiro RJ Brazil http://www.inct-inofar.ccs.ufrj.br http://www.lassbio.icb.ufrj.br.
Aline C de QueirozLaboratório de Farmacologia e Imunologia, Instituto de Ciências Biológicas e da Saúde, Universidade Federal de Alagoas (UFAL) 57072-900 Maceió AL Brazil suzana.magna@gmail.com +55 82 3214 1528.
Anderson Brandão LeiteLaboratório de Farmacologia e Imunologia, Instituto de Ciências Biológicas e da Saúde, Universidade Federal de Alagoas (UFAL) 57072-900 Maceió AL Brazil suzana.magna@gmail.com +55 82 3214 1528.
Felipe T MartinsInstituto de Química, Universidade Federal de Goiás (UFG) Campus Samambaia, CP 131 Goiânia GO 74001-970 Brazil.ORCID https://orcid.org/0000-0001-9004-0927
Antonio C DoriguettoInstituto de Química, Universidade Federal de Goiás (UFG) Campus Samambaia, CP 131 Goiânia GO 74001-970 Brazil.
Eliezer J BarreiroInstituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio, ®), Universidade Federal do Rio de Janeiro (UFRJ), CCS PO Box 68023, Cidade Universitária 21941-902 Rio de Janeiro RJ Brazil http://www.inct-inofar.ccs.ufrj.br http://www.lassbio.icb.ufrj.br.
Magna S Alexandre-MoreiraLaboratório de Farmacologia e Imunologia, Instituto de Ciências Biológicas e da Saúde, Universidade Federal de Alagoas (UFAL) 57072-900 Maceió AL Brazil suzana.magna@gmail.com +55 82 3214 1528.
Lídia M LimaInstituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio, ®), Universidade Federal do Rio de Janeiro (UFRJ), CCS PO Box 68023, Cidade Universitária 21941-902 Rio de Janeiro RJ Brazil http://www.inct-inofar.ccs.ufrj.br http://www.lassbio.icb.ufrj.br.ORCID https://orcid.org/0000-0002-8625-6351

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a neglected parasitic disease, and current treatment includes limitations of toxicity, variable efficacy, high costs and inconvenient doses and treatment schedules. Therefore, new leishmanicidal drugs are still an unquestionable medical need. In this paper we described the design conception of a new framework, the carbamoyl-

Identifiers

PMID35497630
PMCPMC9050848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.